COMPANY Data
My FAVORITES

Movers and SHAKERS
Friday, October 23, 2020
Ceapro (CRPOF)(CZO:CA)
NRC Grant to Produce Coronavirus Therapeutic Candidates by PGX Technology
Noble Capital Markets research on Ceapro is published under ticker symbols (CRPOF and CZO:CA). The price target is in USD and based on ticker symbol CRPOF. Ceapro Inc is engaged in the development and application of proprietary extraction technology to produce extracts and active ingredients from oats and other renewable plant sources. Its operating segments are the Active ingredient product technology industry and the Cosmeceutical industry. The company derives a majority of the revenue from the Active ingredient product technology industry segment which involves the development of proprietary extraction technologies and the application of these technologies to the production and development and commercialization of active ingredients derived from oats and other renewable plant resources for healthcare and cosmetic industries. Geographically, the company has business operations in the U.S, Germany, China, Canada and other countries.
Ahu Demir, Ph. D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
NRC grants financial support to Ceapro’s PGX platform technology. The National Research Council of Canada (NRC) has approved an amendment to Ceapro’s project contributing financial support up to $590,000 for large scale manufacturing of PGX yeast beta-glucan (PGX-YBG) to use in the clinical trials to treat COVID-19 patients.
PGX technology is versatile. We think this grant validates the versatility of Ceapro’s PGX platform technology and capability to produce novel products not only in nutraceutical and cosmeceutical but also in the biopharmaceutical market ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
